CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Stock Information for Kandi Technologies Group Inc.
Loading
Please wait while we load your information from QuoteMedia.